药明生物与清华大学免疫治疗创新中心签署战略合作备忘录
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership
(*Please scroll down for English news.)
药明生物首次与高校建立战略合作伙伴关系
全球领先的开放式生物技术平台公司药明生物（WuXi Biologics, 2269.HK）与清华大学免疫治疗创新中心（ICIT）今日宣布，双方正式签署合作备忘录，建立生物药发现、开发及生产战略合作伙伴关系。
签约仪式现场
ICIT聚焦免疫类和癌症类疾病疗法的发现及开发。通过这次合作，双方将依托清华大学在基础科研的雄厚力量和人才优势，借力药明生物在创新生物药发现、细胞株开发、细胞培养工艺开发、纯化工艺开发、制剂开发及生产领域强大的一体化生物制药能力和技术赋能平台，助力ICIT的单克隆抗体、双特异性抗体、重组蛋白和蛋白偶联物等抗体药物开发。
“清华大学经过6年的积累，已经在免疫学集聚了一批优秀学者，原创成果不断涌现。随着ICIT的建立，并与药明生物建立战略合作关系，都将促进科研成果转化，造福社会和国民经济。”清华大学医学院院长、免疫学研究所所长董晨教授表示。
“我很高兴能促成我的母校清华大学与我们公司的这一战略合作，药明生物将赋能ICIT科研成果加速实现转化。”药明生物首席执行官陈智胜博士表示，“ICIT拥有大量的优秀人才储备，我们非常期待药明生物的首个与高校科研院所的战略合作。作为一家生物制药能力和技术平台，药明生物不仅能赋能全球生物制药产业的企业，还能为全球生物制药领域科学家、高校及科研机构等不同合作伙伴赋能，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。”
关于清华大学免疫治疗创新中心（ICIT）
清华大学免疫治疗创新中心由清华大学免疫学研究所与清华大学技术转移研究院于2016年8月联合创建，免疫学研究所董晨所长和技术转移研究院金勤献院长担任中心共同主任。ICIT旨在推动创新的技术孵化模式，在免疫原创研究的基础上，通过与国际知名药企建立战略合作，培育基础研究成果转化为免疫治疗药物，从而加速实现免疫学科研成果的临床应用。
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。
WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership
BEIJING and SHANGHAI, May 30, 2018
WuXi Biologics’ first strategic partnership with a university
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Tsinghua University Innovation Center for Immune Therapy (ICIT), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in discovery, development and manufacturing of biologics.
ICIT focuses on discovery and development of therapies for immune and cancer diseases. Through this partnership ICIT will have access to WuXi Biologics’ comprehensive, integrated services include innovative biologics discovery, cell line development, cell culture process development, purification process development and formulation development and manufacturing for ICIT’s monoclonal antibodies, bispecific antibodies, recombinant proteins, and protein conjugates (i.e., ADCs).
“Tsinghua University has gathered a number of excellent Immunology scholars after six-year accumulation, and original achievements are constantly emerging. The establishment of ICIT and the strategic partnership between ICIT and WuXi Biologics will not only accelerate transformation of achievements in scientific research, but also benefit the society and the national economy,” said Prof. Chen Dong, Dean of School of Medicine, and Director of the Institute for Immunology, Tsinghua University.
“I am greatly excited and honored to promote the collaboration between my alma mater and our company to enable the translation of scientific research achievements in ICIT,” said Dr. Chris Chen, CEO of WuXi Biologics. “ICIT has a strong talent pool and we are looking forward to our first-ever strategic partnership with a research institute. WuXi Biologics is a platform company enabling not only our global partners, but also scientists, universities and institutes in the global biologics industry. We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing, and we are committed to expediting biologics development with reduced R&D costs to benefit patients worldwide.”
Tsinghua University Innovation Center for Immune Therapy (ICIT), a joint entity of the Institutes for Immunology and Institute of Technology Transfer at Tsinghua University, was established in August, 2016. ICIT aims to accelerate transformation of basic scientific discoveries into innovative medicines. ICIT thus serves as an “incubator” for translational research “from target to hit” by providing seed money as well as technical expertise. The successful applications are expected to have sound scientific basis and carefully crafted plan to develop first-in-class lead molecules for immune-related diseases.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议
